BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25735000)

  • 1. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine.
    Cernuda-Morollón E; Ramón C; Martínez-Camblor P; Serrano-Pertierra E; Larrosa D; Pascual J
    Pain; 2015 May; 156(5):820-824. PubMed ID: 25735000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
    Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
    Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
    Domínguez C; Vieites-Prado A; Pérez-Mato M; Sobrino T; Rodríguez-Osorio X; López A; Campos F; Martínez F; Castillo J; Leira R
    Headache; 2018 Jan; 58(1):78-87. PubMed ID: 29131327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [No Abstract]   [Full Text] [Related]  

  • 5. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
    Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
    Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine.
    Cernuda-Morollón E; Larrosa D; Ramón C; Vega J; Martínez-Camblor P; Pascual J
    Neurology; 2013 Oct; 81(14):1191-6. PubMed ID: 23975872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine.
    Domínguez Vivero C; Leira Y; Saavedra Piñeiro M; Rodríguez-Osorio X; Ramos-Cabrer P; Villalba Martín C; Sobrino T; Campos F; Castillo J; Leira R
    Toxins (Basel); 2020 Jul; 12(8):. PubMed ID: 32731573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice.
    Pérez-Pereda S; Toriello-Suárez M; Ocejo-Vinyals G; Guiral-Foz S; Castillo-Obeso J; Montes-Gómez S; Martínez-Nieto RM; Iglesias F; González-Quintanilla V; Oterino A
    Mol Biol Rep; 2020 Sep; 47(9):7125-7138. PubMed ID: 32951099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine.
    Ramón C; Cernuda-Morollón E; Pascual J
    Curr Opin Neurol; 2017 Jun; 30(3):281-286. PubMed ID: 28234796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interictal amylin levels in chronic migraine patients: A case-control study.
    Irimia P; Martínez-Valbuena I; Mínguez-Olaondo A; Domínguez-Vivero C; Sánchez-Arias JA; Martínez-Vila E; Luquin MR; Leira R
    Cephalalgia; 2021 Apr; 41(5):604-612. PubMed ID: 33269952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?
    Cernuda-Morollón E; Ramón C; Larrosa D; Alvarez R; Riesco N; Pascual J
    Cephalalgia; 2015 Sep; 35(10):864-8. PubMed ID: 25431141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal.
    Lee MJ; Lee SY; Cho S; Kang ES; Chung CS
    J Headache Pain; 2018 Jul; 19(1):53. PubMed ID: 30006780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
    Ruscheweyh R; Athwal B; Gryglas-Dworak A; Frattale I; Latysheva N; Ornello R; Pozo-Rosich P; Sacco S; Torres Ferrus M; Stark CD
    Headache; 2020 Sep; 60(8):1673-1682. PubMed ID: 32797631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild systemic inflammation enhances response to OnabotulinumtoxinA in chronic migraineurs.
    Leira Y; Domínguez C; Ameijeira P; López-Arias E; Ávila-Gómez P; Pérez-Mato M; Sobrino T; Campos F; Blanco J; Leira R
    Sci Rep; 2021 Jan; 11(1):1092. PubMed ID: 33441852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Frequent episodic migraine and calcitonin gene-related peptide. Influence of treatment with topiramate and zonisamide on levels of the peptide].
    Garcia-Estevez DA; Pardo-Parrado M; Silvarrey-Rodriguez S
    Rev Neurol; 2017 Aug; 65(4):153-156. PubMed ID: 28726232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review.
    Salim A; Hennessy E; Sonneborn C; Hogue O; Biswas S; Mays M; Suneja A; Ahmed Z; Mata IF
    CNS Drugs; 2024 Jun; 38(6):481-491. PubMed ID: 38583127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An academic debate: OnabotulinumtoxinA for chronic migraine: PREEMPT-derived vs "customized" dosing/injection paradigm.
    Green MW; Rothrock JF
    Toxicon; 2018 Jun; 147():116-119. PubMed ID: 29596847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
    Aicua-Rapun I; Martínez-Velasco E; Rojo A; Hernando A; Ruiz M; Carreres A; Porqueres E; Herrero S; Iglesias F; Guerrero AL
    J Headache Pain; 2016 Dec; 17(1):112. PubMed ID: 27957623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients.
    Eren OE; Gaul C; Peikert A; Gendolla A; Ruscheweyh R; Straube A
    Sci Rep; 2020 Jul; 10(1):11382. PubMed ID: 32647152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls.
    Kamm K; Straube A; Ruscheweyh R
    Cephalalgia; 2019 Oct; 39(12):1535-1543. PubMed ID: 31603037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.